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rug drug interaction, is an important 
cause for disturbing of medical manage-
ment of a disease that usually is preven-
tive, must be continuously investigated for detection of 
causes. Due to little data about it in recently years in this 
area, study was done, to investigate of quantity of inter-
actions, and some related factors. In this cross sectional 
study, all prescriptions data from April to October 2016 
were collected. Variable data included: type and name 
of drugs- the number of drugs in each prescription and 
characteristics of interactions. We used software of drug 
interaction fact and lexicomp on desk top DI and textbook 
‘Drug Interaction Facts’ .Statistical analysis done by t test 
and use of SPSS 19. Finally, 41096 prescriptions were col-
lected. From these data 56% were male. 3043 of subjects 
had DDI (7.4%). most interaction was in 5th degree and 
majority of interactions were mild. DDI between ammo-
nium chloride and pseudoephedrine –antihypertensive 
drugs and others-omeprazole and chlordiazepoxide had 
the most frequency, respectively.  About interaction show, 
53% was delay and 43% was rapid. The mean quantity of 
drugs was less than four type drugs in each prescription. 
We conclude that, general and even OTC drug had great 
DDI that must be notice to these drugs in prescriptions. 
There was no correlation between gender or specialty 
of physician and frequency of DDI (p=0.08). Quantity 
of drugs in each prescription, correlate with rate of DDI 
(p=.003). Attendance a pharmacist in treatment team of 
patients could be helpful, for decrease the rate of DDI. In 
all centers, continuous and more research for detecting 
DDI is necessary.
Keywords: drug interaction, DDI, physician.
a interacción farmacológica, es una causa 
importante para alterar el manejo médico de 
una enfermedad que generalmente es pre-
ventiva, debe investigarse continuamente para detectar 
causas. Debido a la poca información al respecto en los 
últimos años en esta área, se realizó un estudio para inves-
tigar la cantidad de interacciones y algunos factores rela-
cionados. En este estudio transversal, se recopilaron todos 
los datos de las prescripciones de abril a octubre de 2016. 
Los datos variables incluyeron: tipo y nombre de los medi-
camentos: la cantidad de medicamentos en cada receta y 
las características de las interacciones. Usamos software 
de hechos de interacción de drogas y lexicomp en el escri-
torio y en el libro de texto “Datos de interacción de dro-
gas”. Análisis estadístico realizado mediante la prueba t y 
uso de SPSS 19. Finalmente, se recogieron 41096 recetas. 
De estos datos el 56% eran hombres. 3043 de los sujetos 
tenían DDI (7,4%). la mayor parte de la interacción fue 
de 5 t h grado y la mayoría de las interacciones fueron 
leves. La DDI entre el cloruro de amonio y la pseudoefed-
rina (medicamentos antihipertensivos y otros), omeprazol 
y clordiazepóxido tuvieron la mayor frecuencia, respec-
tivamente. Sobre el programa de interacción, el 53% fue 
retraso y el 43% fue rápido. La cantidad media de medi-
camentos fue menos de cuatro medicamentos de tipo en 
cada receta. Llegamos a la conclusión de que, en general, 
e incluso el medicamento de venta libre tuvo un gran DDI 
que debe notificarse a estos medicamentos en las recetas. 
No hubo correlación entre el sexo o la especialidad del 
médico y la frecuencia de DDI (p=0.08). La cantidad de 
medicamentos en cada receta, se correlaciona con la tasa 
de DDI (p=.003). La asistencia de un farmacéutico en el 
equipo de tratamiento de pacientes podría ser útil para 
disminuir la tasa de DDI. En todos los centros, es necesaria 
una investigación continua y más para detectar DDI.
Palabras clave: interacción farmacológica, DDI, médico.
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edical errors are life threatening 
events in management of diseases.
for increasing safety of patients; 
physician must be noticed to their causes.  DDI (drug drug 
interactions), is an important cause for disturbing of medi-
cal management of a disease. 
Patients frequently use more than one medication at a 
time. Unanticipated, unrecognized, or mismanaged DDIs 
are important causes of morbidity and mortality associ-
ated with prescription drug uses that usually are preven-
tive1,2.
Patients, often come to physician with a legacy of drugs, 
during previous medical experience that if physician not 
notice to it, risk of DDI may be increased. Some groups of 
patients, especially old age with multiple long standings 
disease are predisposed to DDI3.
Drug interaction is defined as the pharmacologic or clinical 
responses to administration of a drug combination, differ-
ing from the anticipated known effect of two agents.
Combining drugs may cause pharmacokinetic and/or phar-
macodynamics interactions. Pharmacokinetic mechanisms 
of interaction include alterations of absorption, distribu-
tion, biotransformation, or elimination. Pharmacokinetic 
interactions in general result in an altered concentration 
of active drug or metabolite in the body, modifying the 
expected therapeutic response. Interaction must be con-
sidered in differential diagnosis of any unusual responses 
occurring during drug treatment4,5,6. 
Beside above, DDI may be occurring between prescription 
drugs but also between food& drug and chemical and 
drug.it  is a dynamic problem , belong to all time and lo-
cation.it must be continuously investigated for detection 
of causes and preventive schedule of it. Due to little data 
about it in recently years in this area, the aim of this study 
is to investigate of quantity of interactions, and to assay 
what physicians’ prescriptions cause more interactions 
and to identify common interactions. 
n this cross sectional study, all prescriptions data 
from April to October 2016 were collected. These 
data were belonging to 2 general hospital pharma-
cies affiliated to Lorestan University of medical sciences (in 
capital of province). 
All outpatients and inpatients prescriptions were enrolled 
in study. Variable data included: type and name of drugs 
- the number of drugs in each prescription - physician spe-
cialty and gender, and characteristics of interactions. For 
detection of DDI, we used software of drug interaction 
fact and lexicomp on desk top DI. Also, we used reference 
textbook ‘Drug Interaction Facts’ published in 2010 for 
completion of study7.
 Mean +/- SD and percentage parameters were used.Sta-
tistical analysis done by t test and use of SPSS version 19. 
P value less than 0.05 was considered significant.
inally, 41096 prescriptions were collected. From 
these data 56% were male and others female sub-
jects. Minimum age of patients was 2 and maximum age 
was 89 years old. Average subject age was 35.5 years old.
 Out of all them, 3043 subjects had DDI (7.4%).based 
on importance, most interaction was in 5th degree and 
respectively, 3th and 2th degrees were common. Between 
all DDIs, majority of interactions were mild. About interac-
tion show, 53% was delay and 43% was rapid summa-
rized data was showed in fig 1.
In this study, most of DDIs belong to combination of pseu-
do ephedrine and ammonium chloride (in diphenhydr-
amine compound), then respectively: antihypertensive 





























Fig 1. Percentile of DDI characteristics
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In between all prescriptions, NSAIDs – corticosteroids –
azithromycin –metoclopramide were the most frequent 
type of prescribed drugs.
The most quantity of drugs was four type drugs in each 
prescription. Between one and ten drugs type prescribed 
in total of papers. Distribution of drugs numbers in each 
prescription was summarized in figure 2.
Between all paper contained DDI, 59% was prescribed by 
general practitioners and 41% by specialist.
n term of the DDI severity, interactions can be classi-
fied by: Mild interaction denotes that they are not of 
clinical importance or the effect on the interaction 
has not been established. Moderate interaction means, 
that possible changes in therapeutic effect or may cause 
adverse effects, but can be avoided adjusting the drug 
doses.  Major interaction means, result in potential ad-
verse effects and necessitates individual dose adjustment 
in the cases.
About time of onset of action: rapid means that the ef-
fect will be evident within 24 hr, after administration of 
drugs and delay reaction means that the effect will not be 
evident until days or weeks.
About importance of interaction: they divided in five 
groups. 1. Established: proven to occur in well controlled 
studies, 2. probable: very likely but not proven clinically, 
3. suspected: may occur; need more study, 4. possible: 
could occur but data are limited, 5. Unlikely:  doubtful; no 
good evidence of an altered clinical effect.
At first, in review of literature, we conclude that, there 
is wide variability between frequencies of DDI in the all 
centers. In ahmadizadeh study in Iran 77% and in namazi 
study at least 1 DDI in 43%of all patients reported8,9.
In other study (in birjand .Iran), 42% of prescription had 
DDI. Also, similar study out of Iran showed wide variability 
in DDI frequency. 18.5% in Greece and9.8% in Finland 
and 41% in Nepal10-13.
 In comparison, we could not detect any rational rela-
tion between or result and other study about frequency 
of DDI. We noticed to methodological effect of studies-
different distribution of people age and sex and diversity 
of type of disease and specialty of physician – time and 
location of studies for this variation of results. For example 
some studies, only evaluate patients in critical ward that 
increase the rate of DDI due to longer admission of pa-
tients14. Previous study in 2013 showed that drug interac-
tions are somewhat inevitable and like other provinces15. 
Finally, we suggested that each group of patients must be 
compare with same groups in other time and other posi-
tion but no other population.
In our study, the most frequent DDI occurred between 
ammonium chloride (in diphenhydramine compound) 
and pseudoephedrine, although these reactions are mild. 
After it, the most important reaction (related to moder-
ate- severe reactions), was seen between antihypertensive 
drugs with others. Especially, angiotensin receptor block-
ers or angiotensin converting enzyme inhibitors and di-
uretics had more reaction versus other antihypertensive 
drug. We noticed to multiple prescriptions of these types 
of drugs, because of high frequency of uncontrolled hy-
pertension in this area. Another frequent DDI was seen 
between beta blockers (especially, propranolol) and ac-
etaminophen. Notwithstanding, NSAIDs, corticosteroids, 
azithromycin had the most quantity of prescribed drug   in 
all subjects.
In nabovati study, beta blockers and diuretics and in Far-
zaneh study, Aspirin had most frequent drug interaction 
in prescriptions16,17, previous study in east of Iran showed 
that, dexamethasone & ranitidine and then corticosteroids 
& NSAIDs had majority of DDI18. Interaction between beta 
adrenergic blockers and glimepiride (oral hypoglycemic 
agents) was the most commonly observed interaction in 
Jaskumar  Nk  study19.
We conclude that, general and even OTC drug (not spe-
cialized drugs), had great DDI and physicians must be no-
tice to these general drugs in prescriptions.in majority of 
studies, only limited drugs included in DDI that necessities 
awareness of prescribers20.
Similar to other study, there was no significant relation 
between gender of patients and rate of DDI In our study 
(Esmaeil Farzaneh, & Khouri et al study)17,21.
Our result showed that, no correlation between gender 
or specialty of physician and frequency of DDI was docu-
mented (p=0.08), but in other study, male gender was 
factor for drug interaction in mousavi study, specialist had 
more DDI in their prescription than general practitioners, 
in Ardabil study, 84.8% of drug interactions have ben 
occurred by male and 15.2% by female physicians and 
there was significant relation between sex of physician 








and number of interferences in mousavi study, Medical 
specialist’s prescriptions in comparison with general prac-
titioners  had significantly more moderate severity interac-
tions. Similar results reported in podasani study22,23.
In our study, DDI severity, classified as: 2.3% in severe cat-
egory and 17.7% in moderate and 80% in mild category. 
There is some difference between characteristic of DDI  in 
our study and others.in previous study in Kurdistan 15.6% 
,42.6% and 41.8% of interaction were severe, moder-
ate and mild respectively, in gorgan study result was: 
35.5%,63.1% and 1.4% respectively24,25.
We suppose that some factor, including: type of disease 
may be influence on the type of drugs resulting in varia-
tion of DDI in different centers. We supposed that, dura-
tion time of disease management, variation of patients’ 
age, and other comorbidity, especially: renal or hepatic 
disease and hemodynamic instability may be influence on 
the interaction between drugs in different studies38-40.  
Previous studies showed that 1.3 -2.1 mean drug in each 
paper is suitable for reducing risk of DDI26-28. In this study, 
mean number of drugs in each prescription was 3.8 that 
was near to other studies (by Soleymani and mousavi)29,30. 
Previous study by nabovati and et al (in Iran), showed that 
mean number of drugs in each prescription is high16. In 
our study, quantity of five drugs type in each prescrip-
tion had more rate of DDI than fewer quantities. Analyses 
show that quantity of drugs in each prescription, corre-
late with rate of DDI (p=.003). We conclude, the multi-
drug prescription may be a risk factor for DDI, this result 
documented in previous studies31-33. Patients with 2 or 
more disorders may be use different type of drugs result 
in more DDI34.
Increased knowledge of practitioners, for Better diagnosis 
of disease may decrease the quantity of drugs in prescrip-
tion, although some chronic and end stage patients need 
more and more drugs35,36.
Physician in subspecialty, due to visit of more complicated 
patients and especially, physician in ICU must be notice to 
more risk of prescription with DDI.
Finally, for reduction rate of DDI below approaches is rec-
ommended:
1. Documentation of all drugs, including over-the- coun-
ters.
2. Reduce the number of prescriptions drugs in each pre-
scription.
3. be especially vigilant in high risk situations: elderly, pa-
tients in an intensive care unit, or with co-morbid ill-
nesses such as renal or hepatic failure.
4. more knowledge about the pharmacology of the drugs 
, route of excretion, the type of liver or renal metabo-
lism if it exists, the half- life of the drug, and its bioavail-
ability.
If there is an unexpected deterioration or change in the 
patient condition, consider drug- drug interactions, which 
usually present in a subtle manner.  We (and others), con-
clude that use of software for detects of DDI or atten-
dance a pharmacist in treatment team of patients could 
be helpful, for decrease the rate of DDI37.
Drug interactions are tricky and are easy to miss if not 
quite. More and more research for detecting type and fre-
quency of DDI in much prescription may turn on a light for 
solving the problem.
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